{"id":65567,"date":"2026-05-18T14:56:42","date_gmt":"2026-05-18T06:56:42","guid":{"rendered":"https:\/\/flcube.com\/?p=65567"},"modified":"2026-05-18T14:56:42","modified_gmt":"2026-05-18T06:56:42","slug":"harbour-biomed-unveils-preclinical-data-for-let003-ai-discovered-acvr2a-2b-antibody-shows-best-in-class-potential-in-obesity-combination-therapy-with-glp-1-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65567","title":{"rendered":"Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs"},"content":{"rendered":"\n<p><strong>Harbour BioMed<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2142:HKG\">HKG: 2142<\/a>) has published preclinical data for <strong>LET003<\/strong>, an <strong>ACVR2A\/2B-targeted monoclonal antibody (mAb)<\/strong> developed using the company&#8217;s proprietary <strong>Hu-mAtrIx artificial intelligence (AI) platform<\/strong>. The investigational therapy demonstrates potential to address a critical limitation of current GLP-1 weight-loss drugs by <strong>preserving lean body mass while enhancing fat reduction<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-innovation\">Drug Profile &amp; Innovation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Molecule<\/strong><\/td><td>LET003 \u2013 human monoclonal antibody targeting ACVR2A\/2B<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Harbour BioMed&#8217;s Hu-mAtrIx AI-driven antibody discovery platform<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Dual blockade of ACVR2A\/2B signaling pathway regulating fat-muscle balance<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical (data publication)<\/td><\/tr><tr><td><strong>Key Innovation<\/strong><\/td><td>First AI-discovered ACVR2A\/2B antibody optimized for obesity combination therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-rationale-amp-therapeutic-opportunity\">Scientific Rationale &amp; Therapeutic Opportunity<\/h2>\n\n\n\n<p>The <strong>ACVR2A\/2B signaling pathway<\/strong> plays a pivotal role in regulating the body&#8217;s <strong>fat-to-muscle balance<\/strong>. Current <strong>GLP-1 receptor agonists<\/strong> (semaglutide, tirzepatide) achieve significant weight loss but result in substantial <strong>lean body mass loss<\/strong> (approximately 30-40% of total weight lost), which can negatively impact metabolic health and physical function.<\/p>\n\n\n\n<p><strong>LET003 addresses this unmet need by:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Blocking ACVR2A\/2B signaling to promote muscle preservation during weight loss<\/li>\n\n\n\n<li>Enhancing fat-specific reduction when combined with GLP-1 therapies<\/li>\n\n\n\n<li>Potentially improving long-term metabolic outcomes through body composition optimization<\/li>\n\n\n\n<li>Enabling more sustainable weight management through preserved muscle mass<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-data-highlights\">Preclinical Data Highlights<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharmacokinetic-superiority\">Pharmacokinetic Superiority<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Superior PK properties<\/strong> compared to multiple competitor molecules in the same class<\/li>\n\n\n\n<li>Optimized half-life and exposure profile supporting once-weekly or less frequent dosing<\/li>\n\n\n\n<li>Enhanced tissue penetration and target engagement characteristics<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-combination-therapy-efficacy-with-semaglutide\">Combination Therapy Efficacy (with Semaglutide)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Significantly enhanced fat reduction<\/strong> compared to semaglutide monotherapy<\/li>\n\n\n\n<li><strong>Effective preservation of lean body mass<\/strong> during active weight loss phase<\/li>\n\n\n\n<li>Synergistic effects on body composition without additive toxicity<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-benchmarking-vs-bimagrumab\">Competitive Benchmarking vs. Bimagrumab<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Comparable lean body mass gain<\/strong> to bimagrumab (same target, higher dose)<\/li>\n\n\n\n<li>Achieved at <strong>lower therapeutic dose<\/strong>, suggesting improved therapeutic index<\/li>\n\n\n\n<li>Potential for reduced side effects and manufacturing cost advantages<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<p>The <strong>global obesity therapeutics market<\/strong> is projected to exceed <strong>$100 billion by 2030<\/strong>, driven by GLP-1 drug success. However, <strong>body composition concerns<\/strong> represent a significant barrier to optimal patient outcomes and long-term adherence.<\/p>\n\n\n\n<p><strong>Current competitive landscape includes:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bimagrumab<\/strong> (Novartis) \u2013 ACVR2A\/2B antibody in Phase 2 for obesity\/sarcopenia<\/li>\n\n\n\n<li><strong>ACE-031<\/strong> (Acceleron) \u2013 Earlier generation ACVR2A\/2B fusion protein (development discontinued)<\/li>\n\n\n\n<li><strong>Multiple GLP-1\/GIP\/glucagon triple agonists<\/strong> \u2013 Focused on enhanced weight loss but not body composition<\/li>\n<\/ul>\n\n\n\n<p><strong>LET003&#8217;s competitive advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI-optimized molecular design<\/strong> for superior pharmacokinetics<\/li>\n\n\n\n<li><strong>Lower effective dose<\/strong> compared to existing same-target approaches<\/li>\n\n\n\n<li><strong>Combination-ready profile<\/strong> specifically designed for GLP-1 co-administration<\/li>\n\n\n\n<li><strong>Chinese innovation leadership<\/strong> in next-generation obesity therapeutics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> Success validates Harbour BioMed&#8217;s Hu-mAtrIx AI platform for complex therapeutic targets<\/li>\n\n\n\n<li><strong>Global Partnership Potential:<\/strong> Strong preclinical data may attract international pharma collaboration interest<\/li>\n\n\n\n<li><strong>Market Differentiation:<\/strong> Positions Harbour BioMed at forefront of body composition-focused obesity therapeutics<\/li>\n\n\n\n<li><strong>Development Acceleration:<\/strong> Robust preclinical package supports rapid clinical translation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps-amp-timeline\">Next Steps &amp; Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IND-enabling studies<\/strong> expected to commence in Q3 2026<\/li>\n\n\n\n<li><strong>Phase 1 clinical trial<\/strong> anticipated to begin in early 2027<\/li>\n\n\n\n<li><strong>Combination studies with GLP-1 drugs<\/strong> planned as part of clinical development program<\/li>\n\n\n\n<li><strong>Global regulatory strategy<\/strong> under evaluation for major markets (US, EU, China)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding preclinical data, development plans, and market potential for LET003. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Harbour BioMed (HKG: 2142) has published preclinical data for LET003, an ACVR2A\/2B-targeted monoclonal antibody (mAb)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[99,190,916,86],"class_list":["post-65567","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ai","tag-harbour-biomed","tag-hkg-2142","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Harbour BioMed (HKG: 2142) has published preclinical data for LET003, an ACVR2A\/2B-targeted monoclonal antibody (mAb) developed using the company&#039;s proprietary Hu-mAtrIx artificial intelligence (AI) platform. The investigational therapy demonstrates potential to address a critical limitation of current GLP-1 weight-loss drugs by preserving lean body mass while enhancing fat reduction.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65567\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs\" \/>\n<meta property=\"og:description\" content=\"Harbour BioMed (HKG: 2142) has published preclinical data for LET003, an ACVR2A\/2B-targeted monoclonal antibody (mAb) developed using the company&#039;s proprietary Hu-mAtrIx artificial intelligence (AI) platform. The investigational therapy demonstrates potential to address a critical limitation of current GLP-1 weight-loss drugs by preserving lean body mass while enhancing fat reduction.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65567\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-18T06:56:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65567#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65567\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\\\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs\",\"datePublished\":\"2026-05-18T06:56:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65567\"},\"wordCount\":564,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"Harbour BioMed\",\"HKG: 2142\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65567#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65567\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65567\",\"name\":\"Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\\\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-18T06:56:42+00:00\",\"description\":\"Harbour BioMed (HKG: 2142) has published preclinical data for LET003, an ACVR2A\\\/2B-targeted monoclonal antibody (mAb) developed using the company's proprietary Hu-mAtrIx artificial intelligence (AI) platform. The investigational therapy demonstrates potential to address a critical limitation of current GLP-1 weight-loss drugs by preserving lean body mass while enhancing fat reduction.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65567#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65567\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65567#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\\\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs - Insight, China&#039;s Pharmaceutical Industry","description":"Harbour BioMed (HKG: 2142) has published preclinical data for LET003, an ACVR2A\/2B-targeted monoclonal antibody (mAb) developed using the company's proprietary Hu-mAtrIx artificial intelligence (AI) platform. The investigational therapy demonstrates potential to address a critical limitation of current GLP-1 weight-loss drugs by preserving lean body mass while enhancing fat reduction.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65567","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs","og_description":"Harbour BioMed (HKG: 2142) has published preclinical data for LET003, an ACVR2A\/2B-targeted monoclonal antibody (mAb) developed using the company's proprietary Hu-mAtrIx artificial intelligence (AI) platform. The investigational therapy demonstrates potential to address a critical limitation of current GLP-1 weight-loss drugs by preserving lean body mass while enhancing fat reduction.","og_url":"https:\/\/flcube.com\/?p=65567","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-18T06:56:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65567#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65567"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs","datePublished":"2026-05-18T06:56:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65567"},"wordCount":564,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","Harbour BioMed","HKG: 2142","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65567#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65567","url":"https:\/\/flcube.com\/?p=65567","name":"Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-18T06:56:42+00:00","description":"Harbour BioMed (HKG: 2142) has published preclinical data for LET003, an ACVR2A\/2B-targeted monoclonal antibody (mAb) developed using the company's proprietary Hu-mAtrIx artificial intelligence (AI) platform. The investigational therapy demonstrates potential to address a critical limitation of current GLP-1 weight-loss drugs by preserving lean body mass while enhancing fat reduction.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65567#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65567"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65567#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed Unveils Preclinical Data for LET003 \u2013 AI-Discovered ACVR2A\/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65567"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65567\/revisions"}],"predecessor-version":[{"id":65568,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65567\/revisions\/65568"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}